Bio-Techne (TECH) Cash & Current Investments (2009 - 2026)

Bio-Techne has reported Cash & Current Investments for 18 years, with the latest figure at $209.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 49.16% year-over-year to $209.8 million; the trailing twelve-month figure through Mar 2026 stood at $209.8 million (up 49.16% YoY), and the FY2025 full-year result was $165.0 million, up 2.12% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $209.8 million, up from $172.9 million in the prior quarter.
• The five-year high for Cash & Current Investments was $247.0 million in Q2 2022, with the low at $135.7 million in Q4 2023.
• Average Cash & Current Investments over 5 years is $179.4 million, with a median of $172.9 million recorded in 2025.
• Year-over-year, Cash & Current Investments slumped 32.0% in 2023 and jumped 49.16% in 2026.
• Tracing TECH's Cash & Current Investments over 5 years: stood at $196.8 million in 2022, then slumped by 31.06% to $135.7 million in 2023, then surged by 33.26% to $180.8 million in 2024, then decreased by 4.37% to $172.9 million in 2025, then advanced by 21.37% to $209.8 million in 2026.
• The last three Cash & Current Investments figures came in at $209.8 million (Q1 2026), $172.9 million (Q4 2025), and $145.0 million (Q3 2025), per Business Quant data.

Peer Comparison